NCT03068624View on ClinicalTrials.gov

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

July 31, 2025

Conditions
Metastatic Malignant Neoplasm in the LiverMetastatic Uveal Melanoma
Interventions
BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Autologous CD8+ SLC45A2-specific T Lymphocytes

Given via hepatic arterial infusion via central catheter

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Ipilimumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER